Opinion

Video

Breaking Down the PAH Cost Burden

Marius Hoeper, MD, discusses the direct medical costs and indirect socioeconomic costs associated with the treatment of pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and patient productivity and quality of life.

Related Videos
Iltefat Hamzavi, MD, an expert on hidradenitis suppurativa
Iltefat Hamzavi, MD, an expert on hidradenitis suppurativa
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Marius Hoeper, MD, an expert on PAH
Marius Hoeper, MD, an expert on PAH
Ioana Preston, MD, a pulmonologist
Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension
Marius Hoeper, MD, an expert on PAH
Ioana Preston, MD, a pulmonologist
Related Content
CH LogoCenter for Biosimilars Logo